Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.

International journal of STD & AIDS·2017
Same author

The effect of alcohol on zinc absorption : Studies using rat small intestinal perfusion.

Biological trace element research·2013
Same author

Important treatment change for Neisseria gonorrhoea.

Journal of forensic and legal medicine·2013
Same author

Clinical care versus ethical obligations: HIV-1 and -2 co-infection with hepatitis B in a pregnant Jehovah's Witness.

International journal of STD & AIDS·2012
Same author

Managing vaccines: defining the remit of primary care and specialist HIV clinics in the delivery of immunization to individuals with HIV infection.

International journal of STD & AIDS·2012
Same author

Acute hepatitis B: the limits of maintaining patient confidentiality.

International journal of STD & AIDS·2011
Same journal

Switching to long-acting anti-retroviral therapy with no baseline resistance data: is there value in proviral DNA sequencing? A single-centre pilot study.

International journal of STD & AIDS·2026
Same journal

A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections.

International journal of STD & AIDS·2026
Same journal

Long-acting injectable cabotegravir/rilpivirine in a pregnant woman living with HIV with hyperemesis gravidarum:a case report and review of literature.

International journal of STD & AIDS·2026
Same journal

BASHH best practice statement on the management of testosterone-associated vulvovaginitis.

International journal of STD & AIDS·2026
Same journal

Diagnostic accuracy of the Xpert HPV assay in women starting antiretroviral treatment in South Africa.

International journal of STD & AIDS·2026
Same journal

Perceptions of acceptability and preferences surrounding a hypothetical syphilis vaccine in Lima, Peru.

International journal of STD & AIDS·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Premature ejaculation: treatment update.

E J McCarty1, W W Dinsmore

  • 1Department of Genitourinary Medicine, Royal Victoria Hospital, Grosvenor Road, Belfast BT126BA, UK. ej_mccarty@hotmail.com

International Journal of STD & AIDS
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

Premature ejaculation (PE) affects millions of men globally. This review covers current treatments and new options for managing this common sexual health concern.

More Related Videos

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification
03:51

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 16, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification
03:51

Treatment of Ejaculatory Duct Obstruction by Seminal Vesiculoscopy Assisted Flow Modification

Published on: December 8, 2023

Area of Science:

  • Urology
  • Sexual Medicine
  • Pharmacology

Background:

  • Premature ejaculation (PE) is the most prevalent male sexual dysfunction, impacting 22-38% of men worldwide.
  • PE causes significant distress and relationship issues for both individuals and their partners.

Purpose of the Study:

  • To review current standard treatments for PE.
  • To explore emerging therapeutic agents and novel approaches for PE management.

Main Methods:

  • Literature review of accepted and novel treatments for premature ejaculation.
  • Analysis of pharmacological and behavioral therapeutic strategies.

Main Results:

  • Current treatments include behavioral therapies and off-label medications (topical anesthetics, SSRIs, PDE5 inhibitors).
  • Research is increasingly focused on novel treatments and on-demand application of existing therapies.

Conclusions:

  • A combined approach of behavioral therapy and medication is the current standard for PE treatment.
  • Ongoing research into new agents and treatment strategies promises improved management options for PE.